{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_13404", "batch_size": 200, "batch_pos": 15, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain high-potency verbs, potent metaphors, superlatives, intensifiers, or critical alert phrases.", "method": "llm_batch", "batch_id": "batch_2_18704", "batch_size": 200, "batch_pos": 4, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 3, "answer": "no", "rationale": "The segment discusses securing vaccines, not the impact of the disease.", "method": "llm_batch", "batch_id": "batch_3_17728", "batch_size": 200, "batch_pos": 148, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_7432", "batch_size": 200, "batch_pos": 145, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 5, "answer": "no", "rationale": "The segment reports deal details but lacks explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_6720", "batch_size": 200, "batch_pos": 142, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 6, "answer": "no", "rationale": "No minimiser + scale contrast found.", "method": "llm_batch", "batch_id": "batch_6_15860", "batch_size": 200, "batch_pos": 116, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_17068", "batch_size": 200, "batch_pos": 106, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
{"Q": 8, "answer": "yes", "rationale": "Details the vaccine deal, stating it 'secures up to 665,000 doses... and includes an option for a further 40 million vaccines', preparedness/capability, without calming keywords.", "method": "llm_batch", "batch_id": "batch_8_11440", "batch_size": 200, "batch_pos": 125, "statement_text": "The deal secures up to 665,000 doses from vaccine manufacturer CSL Seqirus and includes an option for a further 40 million vaccines for a maximum of four years.", "article_id": 1683}
